Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:KRYS NASDAQ:PRAX NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$123.91+0.9%$116.69$5.59▼$148.83$9.83B0.841.10 million shs227,604 shsKRYSKrystal Biotech$311.53+1.9%$263.06$122.80▼$315.17$9.18B0.5296,315 shs71,886 shsPRAXPraxis Precision Medicines$333.78+1.1%$317.78$35.21▼$356.00$9.35B2.76456,037 shs114,506 shsVERAVera Therapeutics$37.88+4.7%$39.96$18.76▼$56.05$2.71B0.961.14 million shs94,967 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+4.36%-2.70%+2.47%+1,729.21%KRYSKrystal Biotech0.00%+14.91%+18.03%+12.14%+131.20%PRAXPraxis Precision Medicines0.00%+1.80%+4.39%+3.28%+760.55%VERAVera Therapeutics0.00%+2.81%-19.65%-17.47%+66.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$123.91+0.9%$116.69$5.59▼$148.83$9.83B0.841.10 million shs227,604 shsKRYSKrystal Biotech$311.53+1.9%$263.06$122.80▼$315.17$9.18B0.5296,315 shs71,886 shsPRAXPraxis Precision Medicines$333.78+1.1%$317.78$35.21▼$356.00$9.35B2.76456,037 shs114,506 shsVERAVera Therapeutics$37.88+4.7%$39.96$18.76▼$56.05$2.71B0.961.14 million shs94,967 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+4.36%-2.70%+2.47%+1,729.21%KRYSKrystal Biotech0.00%+14.91%+18.03%+12.14%+131.20%PRAXPraxis Precision Medicines0.00%+1.80%+4.39%+3.28%+760.55%VERAVera Therapeutics0.00%+2.81%-19.65%-17.47%+66.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.93Moderate Buy$137.1510.69% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.114.04% UpsidePRAXPraxis Precision Medicines 3.00Buy$591.8377.31% UpsideVERAVera Therapeutics 2.75Moderate Buy$79.60110.14% UpsideCurrent Analyst Ratings BreakdownLatest VERA, ABVX, PRAX, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$420.005/8/2026PRAXPraxis Precision Medicines WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$130.00 ➝ $166.005/8/2026PRAXPraxis Precision Medicines BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$843.005/7/2026PRAXPraxis Precision Medicines Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/5/2026KRYSKrystal Biotech EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$300.005/5/2026KRYSKrystal Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$371.00 ➝ $378.005/4/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.004/20/2026ABVXAbivax Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026VERAVera Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$437.004/14/2026PRAXPraxis Precision Medicines Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$510.00(Data available from 5/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/AKRYSKrystal Biotech$417.30M22.01$7.43 per share41.94$42.06 per share7.41PRAXPraxis Precision Medicines$8.55M1,088.38N/AN/A$34.85 per share9.58VERAVera TherapeuticsN/AN/AN/AN/A$8.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.37N/AN/AN/AN/A-146.43%-88.69%5/25/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4841.6429.61N/A53.92%19.25%17.62%N/APRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-60.25%-54.81%N/AVERAVera Therapeutics-$299.61M-$5.54N/AN/AN/AN/A-74.86%-60.18%N/ALatest VERA, ABVX, PRAX, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/25/2026Q1 2026ABVXAbivax-$0.9359N/AN/AN/A$0.40 millionN/A5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/7/2026Q1 2026VERAVera Therapeutics-$1.3284-$1.69-$0.3616-$1.69$0.43 millionN/A5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million3/23/2026Q4 2025ABVXAbivax-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 million2/26/2026Q4 2025VERAVera Therapeutics-$1.34-$1.39-$0.05-$1.39N/AN/A2/19/2026Q4 2025PRAXPraxis Precision Medicines-$3.00-$3.50-$0.50-$3.50$0.26 millionN/A2/17/2026Q4 2025KRYSKrystal Biotech$1.62$1.70+$0.08$1.70$105.30 million$107.11 million2/14/2026Q4 2025ABVXAbivaxN/A-$1.20N/A-$1.20N/A$0.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.758.75KRYSKrystal BiotechN/A9.469.06PRAXPraxis Precision MedicinesN/A10.2210.22VERAVera Therapeutics0.1513.6413.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%KRYSKrystal Biotech86.29%PRAXPraxis Precision Medicines67.84%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AKRYSKrystal Biotech13.10%PRAXPraxis Precision Medicines2.70%VERAVera Therapeutics15.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.29 millionN/ANot OptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.13 millionOptionableVERAVera Therapeutics4071.36 million60.01 millionOptionableVERA, ABVX, PRAX, and KRYS HeadlinesRecent News About These CompaniesVanguard Group Inc. Grows Stake in Vera Therapeutics, Inc. $VERA3 hours ago | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 11 at 2:30 AM | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of "Moderate Buy" from AnalystsMay 11 at 2:30 AM | marketbeat.comThe Bull Case For Vera Therapeutics (VERA) Could Change Following Atacicept’s FDA Priority Review And Ramp-UpMay 11 at 1:11 AM | finance.yahoo.comSwedbank AB Increases Stock Holdings in Vera Therapeutics, Inc. $VERAMay 10 at 7:15 AM | marketbeat.comVera Therapeutics (VERA) Gets a Buy from LifeSci CapitalMay 8 at 10:34 PM | theglobeandmail.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8 at 4:05 PM | globenewswire.comVera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Misses Expectations By $0.36 EPSMay 7, 2026 | marketbeat.comVera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comVera Therapeutics to Participate in the Bank of America Securities 2026 Health Care ConferenceMay 4, 2026 | globenewswire.comPictet Asset Management Holding SA Cuts Stake in Vera Therapeutics, Inc. $VERAApril 29, 2026 | marketbeat.comVera Therapeutics (VERA) to Release Earnings on TuesdayApril 28, 2026 | marketbeat.comVera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 22,951 SharesApril 16, 2026 | insidertrades.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Moderate Buy" by AnalystsApril 16, 2026 | marketbeat.comVera Therapeutics (NASDAQ:VERA) CEO Sells $1,010,991.55 in StockApril 15, 2026 | marketbeat.comAMI Asset Management Corp Makes New $1.44 Million Investment in Vera Therapeutics, Inc. $VERAApril 14, 2026 | marketbeat.comVera Therapeutics, Inc. Class AApril 11, 2026 | edition.cnn.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 10, 2026 | globenewswire.comIs Vera Therapeutics (VERA) Still Attractive After An 87% One Year Share Price SurgeApril 10, 2026 | finance.yahoo.comThese 5 Biotechs Could Be the Next Big GLP-1 Acquisition TargetApril 1, 2026 | 247wallst.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesA Diamond Quality Entry in DIA ETF, or Is It Time to Get Out?By Thomas Hughes | April 17, 2026What's Behind D-Wave's Spring Rally, and Will It Continue?By Nathan Reiff | April 20, 2026Nebius Group Is Trading Near All-Time Highs, Here's How Far It Has ComeBy Ryan Hasson | April 20, 2026Viking Therapeutics Faces Timeline Risk—But Upside Could Be HugeBy Chris Markoch | May 1, 2026Spirits on the Rocks? The Battle for Jack DanielsBy Jeffrey Neal Johnson | April 23, 2026VERA, ABVX, PRAX, and KRYS Company DescriptionsAbivax NASDAQ:ABVX$123.90 +1.17 (+0.95%) As of 10:38 AM Eastern This is a fair market value price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Krystal Biotech NASDAQ:KRYS$311.53 +5.82 (+1.90%) As of 10:38 AM Eastern This is a fair market value price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Praxis Precision Medicines NASDAQ:PRAX$333.78 +3.76 (+1.14%) As of 10:37 AM Eastern This is a fair market value price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Vera Therapeutics NASDAQ:VERA$37.88 +1.69 (+4.67%) As of 10:38 AM Eastern This is a fair market value price provided by Massive. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tapestry Stock Drops After Strong Quarter and Raised Outlook MarketBeat Week in Review – 05/04 - 05/08 Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance The Stars Are Aligning For Apple: Get Ready for $300 3 Under-The-Radar Small Caps Making New All-Time Highs Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
